Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8557762 | 0.90 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL2110039 | 0.90 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL8557889 | 0.86 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL2109207 | 0.85 | ALOX5 (0.49) | ALOX5 | |
| SCHEMBL8553573 | 0.83 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL8553537 | 0.82 | ALOX5 (0.36) | ALOX5 | |
| SCHEMBL8555899 | 0.81 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL8558059 | 0.81 | — | — | |
| SCHEMBL7607693 | 0.79 | ALOX5 (0.41) | ALOX5 | |
| SCHEMBL1445372 | 0.79 | ALOX5 (0.41) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | claimed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | claimed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | claimed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| EP-1871908-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2008-01-02 | — | — | EP | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| EP-1718284-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006105439-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE. AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2006-10-05 | — | — | WO | disclosed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | disclosed |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2005-12-22 | — | — | US | disclosed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | disclosed |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | DECODE GENETICS EHF. (IS) | 2005-05-26 | — | — | US | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5512594-A | ADMINISTERING TO TREAT A MEDICAL CONDITION MEDIATED BY ONE OR MORE LEUKOTRIENES | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | disclosed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 14/4885 |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | ALOX5, ALOX15, ALOX12 | ALOX5 1/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 13/4885 |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.